A new drug targets weight loss differently, leading to a more permanent fat-shedding solution. This is a major difference from GLP-1 receptor agonists, which can cause the body to cannibalize lean mass, including muscle and bone. NHPs put on semaglutide (the drug marketed as Ozempic) alone, they lost 16% of their fat mass, but also 8% of their lean mass. “Lean mass, especially skeletal muscle, is central to strength, stamina and blood sugar regulation, and so its loss is potentially harmful,” says Panella. When they were given both semaglutide and RES-010, however, the weight loss remained permanent, even after both drugs were stopped.